|1.||Sendi, Hossein: 1 article (07/2012)|
|2.||Ryan Caballes, F: 1 article (07/2012)|
|3.||Bonkovsky, Herbert L: 1 article (07/2012)|
|4.||Priziola, Jennifer L: 1 article (06/2010)|
|5.||Smythe, Maureen A: 1 article (06/2010)|
|6.||Dager, William E: 1 article (06/2010)|
|7.||Wiebe, Valerie: 1 article (12/2002)|
|8.||Hamilton, Patti: 1 article (12/2002)|
|9.||Larsen, S E: 1 article (01/2002)|
|10.||Gbadoe, A D: 1 article (01/2002)|
|1.||Falciparum Malaria (Plasmodium falciparum Malaria)
01/01/1990 - "Short-term oral cinchona alkaloids regimens for treatment of falciparum malaria in Madagascar."
07/01/1998 - "We conducted an open randomized clinical study of intrarectal Quinimax (a Cinchona alkaloids association) (20 mg/kg, then 15 mg/kg every 8 h) vs. intravenous Quinimax (8 mg/ kg infused over 4 h every 8 h) for 2 d in 76 children (39 in the intrarectal and 37 in the infusion groups) with cerebral falciparum malaria in Niger. "
07/01/1995 - "Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics."
09/01/1990 - "Combination of quinine, quinidine and cinchonine for the treatment of acute falciparum malaria: correlation with the susceptibility of Plasmodium falciparum to the cinchona alkaloids in vitro."
01/01/2002 - "All children presented uncomplicated falciparum malaria in association with vomiting in 30 cases, a single unrecurring seizure with postictal coma lasting less than 30 minutes in 25 patients, or prostration without neurological manifestations in 9. Injectable quinimax (an association of cinchona alkaloids) was diluted to a concentration of 60 mg base/ml for i.m. "
04/01/1996 - "Malaria is associated with a reduction in the systemic clearance and apparent volume of distribution of the cinchona alkaloids; this reduction is proportional to the disease severity. "
01/01/1987 - "Cinchona alkaloids and malaria."
01/01/1987 - "Malaria and the cinchona alkaloids."
12/12/1981 - "Cinchona alkaloids and malaria."
11/01/1955 - "[Considerations on the utilization of total cinchona alkaloids in malaria prophylaxis]."
03/01/1987 - "The antibody domain controlling reactions between platelet membranes and drug-dependent (dd) antibodies from patients with thrombocytopenia induced by cinchona alkaloids was studied using F(ab')2, Fab, and Fc fragments made from purified dd-IgG. By direct binding radioimmunoassay (RIA) measurements, 20,000 to 50,000 antibody molecules bound per platelet equivalent of purified platelet membranes at apparent saturation with three different antibodies. "
06/01/2010 - "Medications commonly associated with drug-induced thrombocytopenia include glycoprotein IIb/IIIa inhibitors, cinchona alkaloids, antibiotics, anticonvulsants, and heparin. "
11/01/1998 - "Severe thrombocytopenia with haemorrhagic manifestations was reported following exposure to gold salts, non-steroid anti-inflammatory drugs, sulfonamide antibiotics, cinchona alkaloids and vaccines. "
|4.||Hypertension (High Blood Pressure)
12/01/1953 - "Evaluation of treatment in hypertension: effects of cinchona alkaloids."
03/01/1948 - "Effects of oral cinchona alkaloids on circulation of dogs with experimental hypertension."
03/01/1951 - "The lack of effect of oral doses of cinchona alkaloids on the circulation of dogs with renal hypertension; a contrast to their action in neurogenic hypertension."
|5.||Cardiac Arrhythmias (Arrythmia)
|3.||Anti-Bacterial Agents (Antibiotics)
|6.||Immunoglobulin Fc Fragments
|7.||Immunoglobulin G (IgG)